医学与哲学2024,Vol.45Issue(18) :19-23.DOI:10.12014/j.issn.1002-0772.2024.18.04

罕见病药品可及性的伦理考量与策略探索

Ethical Considerations and Strategy Exploration for Rare Disease Drug Accessibility

李鑫 张素雅 马文兵 任璐
医学与哲学2024,Vol.45Issue(18) :19-23.DOI:10.12014/j.issn.1002-0772.2024.18.04

罕见病药品可及性的伦理考量与策略探索

Ethical Considerations and Strategy Exploration for Rare Disease Drug Accessibility

李鑫 1张素雅 1马文兵 1任璐2
扫码查看

作者信息

  • 1. 西安交通大学第一附属医院药学部 陕西西安 710061
  • 2. 西安交通大学第一附属医院急诊中心 陕西西安 710061
  • 折叠

摘要

在罕见病药品可及性方面,我们仍面临着诸多不容忽视的伦理问题,包括企业以经济效益为导向、缺乏大规模的临床研究、医疗机构缺乏采购罕见病药品的激励机制、超说明书使用罕见病药品、资源不公平分配、支付政策不完善等伦理学问题.因此,国家应完善罕见病药品的鼓励政策,强化企业社会责任,确保药品供应稳定.尊重患者临床试验权益,保障伦理安全.医疗机构需以临床需求为导向,确保药品可及性,并规范超说明书使用,保障患者健康权.国家医保政策应关注罕见病患者,建立多方参与的保障机制,促进药品公平可及.

Abstract

In terms of accessibility to rare disease drugs,we still face many ethical issues that cannot be ignored.This includes ethical issues such as enterprises being driven by economic profit,the lack of large-scale clinical research,the lack of incentive mechanisms for medical institutions to purchase rare disease drugs,off-label use of rare disease drugs,unfair distribution of resources,and imperfect payment policies.Therefore,the country should improve the incentive policies for rare disease drugs,strengthen corporate social responsibility,and ensure stable drug supply.It is essential to respect the rights and interests of patients in clinical trials,and safeguard ethical safety.Medical institutions need to be guided by clinical needs,ensure drug accessibility,and regulate off-label drug use to safeguard the right to health of patients.National medical insurance policy should pay attention to rare disease patients,establish a multi-stakeholder protection mechanism,and promote equitable access to drugs.

关键词

罕见病药品/伦理问题/公平医疗权

Key words

rare disease drugs/ethical issues/right to fair healthcare

引用本文复制引用

基金项目

2024年陕西省自然科学基金一般项目(2024SF-YBXM-111)

2023年陕西省药学会医院药量发展研究项目(XM-2023-1-2-7)

出版年

2024
医学与哲学
中国自然辩证法研究会

医学与哲学

CSTPCDCHSSCD北大核心
影响因子:1.314
ISSN:1002-0772
参考文献量1
段落导航相关论文